Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) was already on the radar screens in biotech before this morning. But news showing that the company’s cancer drug carfilzomib has received favorable FDA panel vote has shares surging. The vote was 11-to-1 in favor of recommending approval.
Investors need to keep in mind that a final decision is expected by the end of July, and the FDA drug approval process does not always follow the opinion and guidance of the panels.
The company generated sales of $447 million in 2011 and Thomson Reuters is looking for $299.3 million in sales in 2012 and $348 million in sales in 2013. Unfortunately it is expected to post a loss in both years.
Onyx opened up at $61.46 and the stock is now up 37% at $61.15 right after the open with more than 5 million shares having traded hands. The prior 52-week range was $27.17 to $47.80 and the market cap is now $2.9 billion.
Watch the options trading in the July and August contracts as the trading has been very elevated of late.
JON C. OGG
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.